Iambic to Present New Pre-Clinical NSCLC Data for IAM1363, a Selective Type II Inhibitor for HER2 Cancers, at the 2025 World Conference on Lung Cancer

Iambic to Participate in September Investor Conferences

Former Amgen SVP of Global Research and Renowned Cell Biologist Ray Deshaies Named to Iambic’s Scientific Advisory Board

Revolution Medicines and Iambic Announce Technology and Research Collaboration Using Iambic’s AI Discovery Tools to Pursue New Drug Candidates

Iambic takes the lead for Next-Gen AI Drug Discovery with Lambda

Iambic Named to CNBC’s 2025 Disruptor 50 List

Scaling Multi-Modal and Multi-Task Transformers for Small Molecule Drug Discovery

San Diego NeuralPLexer3: Accurate Biomolecular Complex Structure Prediction with Flow Models

A Phase 1/1b Study of IAM1363, a selective and brain penetrant HER2 inhibitor in participants (pts) with advanced cancers harboring HER2 alterations

IAM1363 is a Potent, Selective, and Irreversible HER2 and Pan-HER2 Mutant Small Molecule Inhibitor for the Treatment of HER2-Driven NSCLC

Enchant v2: Pushing the Boundaries of Predictive Drug Discovery

A Novel KIF18A Inhibitor for Targeting Chromosomal Instability in Cancer (AACR 2025 Poster)

NeuralPLexer3: Accurate Biomolecular Complex Structure Prediction with Flow Models

Enchant whitepaper: Breaking the data wall between lab and clinic

Multi-Modal and Multi-Task Transformer for Small Molecule Drug Discovery

JPM Healthcare Conference 2026 Company Presentation

Promise & Reality: Decoding AI’s Impact On Drug Development

From Models to Medicines: Delivering on the Promise of AI-Driven Drug Discovery

Enchant: A Multi-Modal Transformer Model to Break Down the Data Wall between Preclinical and Clinical Research and Development

Leveraging AI/ML to Engineer Next-Generation HER2 Inhibitors with Enhanced Selectivity and Brain Penetrance

Predictive Drug Discovery with Enchant v2

Iambic will present new preclinical NSCLC data for IAM1363, a potent Type II HER2 inhibitor, at #WCLC25

Fireside chat at the KeyBanc Capital Markets Technology Leadership Forum

Video: Iambic CEO Tom Miller Interview at the NASDAQ MarketSite